All In Biotech

Drug Trial Radar · NCT02571101

A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation

A Prospective, Randomized, Double-blinded, Active-control, 3-Treatment Arm, Parallel, Multi-center, Phase 2 Trial to Evaluate Safety and Efficacy With CDFR0812-15/25mg and CDFR0812-15/50mg Compared to Clomipramine HCl 15mg in Male Patients Diagnosed With Premature Ejaculation

Last checked: Nov 20, 2026Latest source record: Dec 17, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 297 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

297

Planned (sponsor's estimate)

Start

Nov 2015

Primary completion

May 2016

Study completion Jun 2016

Sponsor

Lead sponsor
CTC Bio, Inc.Industry
Sponsor type
Industry
Collaborators
Symyoo
First posted
Oct 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 19 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of on-demand therapy with CDFR0812-15/25mg and CDFR0812-15/50mg compared to on-demand therapy with single-drug administration of Clomipramine HCl 15mg in Korean Male Patients Diagnosed with Premature Ejaculation

Conditions

  • Premature Ejaculation

Interventions

  • CDFR0812-15/25mgDrug

    Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.

  • CDFR0812-15/50mgDrug

    Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.

  • CondenciaDrug

    Contains chlomipramine HCl 15mg.

  • CDFR0812-PlaceboDrug

    Placebo tablet of CDFR0812.

  • Condencia-PlaceboDrug

    Placebo tablet of Condencia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The fold change of IELTTime frame: From 4 weeks to 8 weeks after dosing

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Inje University Ilsan Paik Hospital

    Goyang-si, South Korea · Recruiting

  • National Health Insurance Service Ilsan Hospital

    Goyang-si, South Korea · Recruiting

  • Pusan National University Hospital

    Pusan, South Korea · Recruiting

  • Catholic Medical Center Seoul St. Mary's Hospital

    Seoul, South Korea · Recruiting

  • Ewha Womans University Medical Center

    Seoul, South Korea · Recruiting

  • Korea University Guro Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Catholic university of Korea Uijeongbu St.Mary's Hospital

    Uijeongbu-si, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.